Cargando…

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer

We previously reported the establishment of several types of long-term estrogen-depleted-resistant (EDR) cell lines from MCF-7 breast cancer cells. Type 1 EDR cells exhibited the best-studied mechanism of aromatase inhibitor (AI) resistance, in which estrogen receptor (ER) expression remained positi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Mariko, Hanamura, Toru, Tsuboi, Kouki, Kaneko, Yosuke, Yamaguchi, Yuri, Niwa, Toshifumi, Narui, Kazutaka, Endo, Itaru, Hayashi, Shin-Ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940386/ https://www.ncbi.nlm.nih.gov/pubmed/29765553 http://dx.doi.org/10.18632/oncotarget.25133

Ejemplares similares

Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer
por: Higuchi, Toru, et al.
Publicado: (2016)

Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells
por: Hayashi, Takanori, et al.
Publicado: (2018)

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
por: Lui, Asona, et al.
Publicado: (2016)

Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance
por: Gohno, Tatsuyuki, et al.
Publicado: (2012)

Dramatic Improvement of Pulmonary Tumor Thrombotic Microangiopathy in a Breast Cancer Patient Treated With Bevacizumab
por: Kimura, Aki, et al.
Publicado: (2023)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Development of an invasive ductal carcinoma in a contralateral composite nipple graft after an autologous breast reconstruction: a case report
por: Kimura, Mariko, et al.
Publicado: (2020)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
por: Sadasivam, Kirithika, et al.
Publicado: (2023)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Primary breast lymphoma initially diagnosed as invasive ductal carcinoma: A case report
por: Uenaka, Natsuki, et al.
Publicado: (2021)

Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells
por: Fujii, Ryu‐ichi, et al.
Publicado: (1994)

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
por: Bihani, Teeru, et al.
Publicado: (2014)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus
por: Nishio, Eiji, et al.
Publicado: (2020)

Granulomatous mastitis in a male breast: A case report and review of literature
por: Kawashima, Kei, et al.
Publicado: (2023)

GALNT1 Expression Is Associated with Angiogenesis and Is a Prognostic Biomarker for Breast Cancer in Adolescents and Young Adults (AYA)
por: Oshi, Masanori, et al.
Publicado: (2023)

Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer
por: Hoppe, Reiner, et al.
Publicado: (2016)

Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells
por: Augimeri, Giuseppina, et al.
Publicado: (2020)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
por: Sakaguchi, Koichi, et al.
Publicado: (2019)

Safety and effectiveness of everolimus in maintenance kidney transplant patients in the real-world setting: results from a 2-year post-marketing surveillance study in Japan
por: Hayase, Naomi, et al.
Publicado: (2021)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
por: Juengel, Eva, et al.
Publicado: (2016)

SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
por: Geng, Wenwen, et al.
Publicado: (2023)

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
por: Magnani, Luca, et al.
Publicado: (2017)

A Case of Female Pseudohermaphroditism Caused by Aromatase Deficiency
por: Nagasaki, Keisuke, et al.
Publicado: (2004)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer
por: Kazi, Armina A, et al.
Publicado: (2014)

Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages
por: Gelsomino, Luca, et al.
Publicado: (2020)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus
por: Menghi, Viola, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_54aiob6l38tnf6btert4l8iefb